• Target

    £1,000,000

  • Type

    Equity

  • Close Date

    Apr 15 2019

  • Status

    Live

RISK WARNING: Your capital is at risk. The risks include: the lack of liquidity in this market in terms of being able to realise investments and the loss of the value of investment. When you invest any loss in value will not be covered by the Financial Services Compensation Scheme.
Please read FULL risk warning.

Linear Diagnostics

A point of care diagnostic platform

A pledge is not a commitment. You will be asked to confirm in the next section.

Track
Contact
Companies
House
Twitter

Overview

Linear Diagnostics Limited (LDL) has developed a point of care (POC) molecular diagnostic platform capable of detecting multiple targets from a single sample in 15 minutes. The defining characteristics of the portable low-cost reader and disposable cartridge are speed, simplicity and sensitivity. The platform is designed to offer diagnosis and treatment within a single clinical appointment. Linear Dichroism (LD) is the underlying technology behind the platform.

 A duplex product for Chlamydia and Gonorrhoeae is the initial focus of LDL. This $1bn addressable market is poorly served by remote laboratory-based tests. The Company will build a follow-on pipeline of POC products including  Influenza A and B and Streptococcus B in pregnant women. In addition, it is exploring the potential markers for head trauma. The broad utility of this technology means that there are also longer-term applications in the agritech and defence sectors.

 In 2016 70% of the existing diagnostic tests for Chlamydia and Gonorrhoea were laboratory based Nucleic Acid Amplification Tests (NAAT). Laboratory based diagnosis means that the interval between sample provision and result and treatment may be several weeks and require two clinical visits. This leads to delays in treatment. The UK NHS currently quotes 7-10 days for chlamydia test results and treatment, and up to two weeks for gonorrhoea. This interval between testing and treatment is too long because patients are unlikely to abstain from sex during this period and up to 50% of patients fail to return for the results wasting valuable provider resource.

Deal Manager avatar

Deal Manager
Sonal Shah

  • Sector: Healthcare
  • Region: UK: Midlands
  • Stage: Pre-revenue, over £1m invested to date
  • Eligible Tax: EIS
  • Board Requirement:
  • Pre Money Valuation: £2,000,000
  • Share Price: £6.55
  • Originator: Envestors
This section is currently locked.
Please Sign Up or Log In to unlock.

Team

This section is currently locked.
Please Sign Up or Log In to unlock.

Market

This section is currently locked.
Please Sign Up or Log In to unlock.

Investment

This section is currently locked.
Please Sign Up or Log In to unlock.

Discussions

This section is currently locked.
Please Sign Up or Log In to unlock.

Deal documents

This section is currently locked.
Please Sign Up or Log In to unlock.

Originator


Originator: Envestors

Investment Focus: Equity and Debt

About: Envestors is a FCA regulated corporate finance adviser in the UK and operates an international network of sophisticated investors investing an average of £42,000 in high growth unquoted companies seeking £250,000 to £2m in equity funding.

Contact Name: Oliver Woolley

  • Registered Investors
    Over 1000
  • Investment through platform
    Over £100m